Related Experiment Videos
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft
J Verweij1, K Krzemieniecki, T Kok
1Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1993
Abstract:
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.